![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MEDIGENE REPORTS INTERIM RESULTS ON ONCOLYTIC VIRUS
MEDIGENE REPORTS INTERIM RESULTS ON ONCOLYTIC VIRUS
September 20, 2006
MediGene has announced that the interim analysis of the Phase I/II trial of the cancer-killing virus NV1020 for the treatment of liver metastases in patients suffering from colorectal carcinoma has shown a clear indication of efficacy. Therefore the trial will be continued as scheduled, with the maximum dosage of the viruses.
In the first stage of the trial, 13 patients whose cancer was progressing despite treatment with chemotherapeutics and monoclonal antibodies were medicated with oncolytic viruses different concentrations. A total of four virus injections were administered at weekly intervals through the hepatic artery. Imaging techniques as well as blood analyses verify that the viruses have a dose-dependent therapeutic effect in the patients treated. All patients receiving the maximum dosage showed either disease stabilization or even a clear regression of liver metastases. Moreover, some of the patients showed regressing metastases in other organs as well, which indicates an effect of the viruses even beyond local application.
Since the treatment also shows a good safety profile, the data safety monitoring board has unanimously recommended the continuation of the trial with the maximum dosage. Due to the encouraging efficacy trends, another 18 patients are to be enrolled in the second part of the trial, which is being conducted in several medical centers in the U.S.
NV1020 is designed to selectively multiply in tumor cells, thus destroying the tumor (oncolysis). The treatment could provide a therapeutic alternative against tumors that are inoperable or have developed a resistance to chemotherapy or radiotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct